For part 3 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the favorable safety and efficacy profile of nipocalimab for generalized myasthenia gravis (gMG).
Understanding the ins and outs of a rare disease like atypical hemolytic uremic syndrome (aHUS) is a difficult task for ...
The table below is a review of notable updates that occurred in January 2025 for investigational products in development.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback